Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 9/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722925 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7346709 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL936563 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7145238 | 0.89 | CA2 (0.46) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823736 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823732 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | CA2 4086/4885HTR1A 2632/4885SIGMAR1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.